Search company, investor...

CNSBio

relevarepharma.com

Founded Year

2005

Stage

Unattributed | Alive

Total Raised

$9.13M

Last Raised

$750K | 10 yrs ago

About CNSBio

Relevare Pharmaceuticals, formerly CNSBio, is a specialty pharmaceutical company focused on the development of novel therapies to treat chronic and acute pain. Relevare Pharmaceuticals exciting clinical-stage pipeline is comprised of programs that combine or reposition drugs known to be active at CNS targets that modulate pain perception and transmission, and for which there is strong safety evidence in humans. In April 2010, CNSBio rebranded to Relevare Pharmaceuticals.

Headquarters Location

Level 40 140 William Street

Victoria, 3000,

Australia

Missing: CNSBio's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: CNSBio's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Expert Collections containing CNSBio

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

CNSBio is included in 1 Expert Collection, including Biopharma Tech.

B

Biopharma Tech

5,241 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

CNSBio Frequently Asked Questions (FAQ)

  • When was CNSBio founded?

    CNSBio was founded in 2005.

  • What is CNSBio's latest funding round?

    CNSBio's latest funding round is Unattributed.

  • How much did CNSBio raise?

    CNSBio raised a total of $9.13M.

  • Who are the investors of CNSBio?

    Investors of CNSBio include Biocom and Queensland BioCapital Funds.

  • Who are CNSBio's competitors?

    Competitors of CNSBio include CytImmune Sciences, Glaukos, Alexza Pharmaceuticals, NeurAxon, Altheus Therapeutics, Conatus Pharmaceuticals, Neurogesx, BioRelix, Horizon Therapeutics, Nuon Therapeutics and 12 more.

Compare CNSBio to Competitors

E
Emagin Therapeutics

Emagin Therapeutics develops new and improved drug entities to treat acute, chronic and cancer-related pain and delivery systems for pain management.

T
ThyroChek

ThyroChek is the only available rapid test for elevated TSH approved by the FDA. It is a rapid, qualitative test for elevated TSH, thyroid stimulating hormone, a clinical indicator of hypothyroidism. Screening Devices Canada is producing products for the thyroid health market in the United States which is a market valued at $1.2B annually.

S
Symphony Allegro

Symphony Allegor is a drug company focused on treatment of acute agitation in patients with schizophrenia and bipolar disorder

L
Labopharm

Labopharm is an international, specialty pharmaceutical company that develops improved formulations of currently marketed drugs using the Company's advanced, controlled-release technologies. Labopharm's strategy is to leverage these technologies to develop and commercialize new formulations of existing products that address the market's preference for drugs that offer simplified dosing regimens, improved efficacy or a reduced side effect profile.

N
NeurOP

NeurOp is a biopharmaceutical company developing new medicines to treat central nervous system disorders, including major depression, neuropathic pain and ischemia. The company's mission is to develop a new generation of N-methyl-D-aspartate (NMDA) receptor blockers, which inhibit proteins that play an important role in neuron signaling. Its compounds specifically target the NR2B subtype of these receptors offering an unprecedented opportunity to improve the safety and tolerability of this therapeutic class without compromising efficacy.

I
Intarcia Therapeutics

Intarcia Therapeutics is a biopharmaceutical company based in Boston, Massachusetts. Intarcia is engaged in the development of a pipeline of products for the proprietary Medici Drug Delivery System comprised of three technologies: A stabilization technology that allows for proteins, peptides, antibody fragments, and other highly potent small molecules to be stabilized at or above human body temperatures, a matchstick-sized osmotic mini-pump that is placed under the dermal layer of skin to deliver a continuous and consistent flow of medication, and a placement technology including proprietary tools designed to provide an optimal user experience.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.